| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Jain S | |
| Steward WP | |||
| Mellon JK | |||
| Gescher AJ | |||
| Thorpe JF | |||
| Marczylo TH | |||
| P2860 | cites work | Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). | Q43739435 |
| 5α-Reductase Type 1 Immunostaining is Enhanced in Some Prostate Cancers Compared With Benign Prostatic Hyperplasia Epithelium | Q44610274 | ||
| Soy isoflavones in the treatment of prostate cancer | Q44846552 | ||
| Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial | Q45062085 | ||
| Estimated impact of the Prostate Cancer Prevention Trial on population mortality | Q45288462 | ||
| Oral treatment of the TRAMP mice with doxazosin suppresses prostate tumor growth and metastasis | Q46403090 | ||
| Estimated impact of the prostate cancer prevention trial on population mortality | Q46599276 | ||
| Trends in prostate cancer incidence, mortality and survival in England and Wales 1971-1998. | Q50661098 | ||
| SELECT: the next prostate cancer prevention trial. Selenum and Vitamin E Cancer Prevention Trial. | Q55035197 | ||
| Prediction of male cancer mortality by plasma levels of interacting vitamins: 17-year follow-up of the prospective Basel study | Q71007069 | ||
| Prostate cancer epidemiology | Q73138981 | ||
| Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States | Q73148998 | ||
| Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial | Q73280460 | ||
| Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR | Q73746754 | ||
| Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy | Q74320901 | ||
| Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer | Q77156174 | ||
| Adenocarcina of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition | Q28192056 | ||
| Selenium and vitamin E supplements for prostate cancer: evidence or embellishment? | Q28192709 | ||
| Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols | Q30658549 | ||
| Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer | Q33928521 | ||
| Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia | Q33961645 | ||
| Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study | Q34065827 | ||
| The specific role of isoflavones in reducing prostate cancer risk | Q34308510 | ||
| Selenium and vitamin E cancer prevention trial | Q34400897 | ||
| Prostate cancer in a transgenic mouse | Q34444393 | ||
| The influence of finasteride on the development of prostate cancer | Q34534815 | ||
| Insulin-Like Growth Factors (IGFs), IGF Receptors, and IGF-Binding Proteins in Primary Cultures of Prostate Epithelial Cells* | Q34585385 | ||
| Prevention of prostate cancer with finasteride: US/European perspective | Q35595810 | ||
| Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes | Q36073406 | ||
| The finasteride prostate cancer prevention trial (PCPT)--what have we learned? | Q36215152 | ||
| The association between baseline vitamin E, selenium, and prostate cancer in the alpha-tocopherol, beta-carotene cancer prevention study | Q39466118 | ||
| Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. | Q40560645 | ||
| 5-Alpha-reductase inhibition and prostate cancer prevention | Q40682796 | ||
| Metastatic prostate cancer in a transgenic mouse | Q41167965 | ||
| Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model | Q42461163 | ||
| P433 | issue | 3 | |
| P921 | main subject | prostate cancer | Q181257 |
| phase III clinical trial | Q42824827 | ||
| P304 | page(s) | 207-211 | |
| P577 | publication date | 2007-04-01 | |
| P1433 | published in | Annals of the Royal College of Surgeons of England | Q15751637 |
| P1476 | title | A review of phase III clinical trials of prostate cancer chemoprevention | |
| P478 | volume | 89 |
| Q82748586 | A retrospective analysis illustrating the substantial clinical and economic burden of prostate cancer |
| Q47825566 | A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers. |
| Q34606617 | Chemoprevention of prostate cancer: what can be recommended to patients? |
| Q37449796 | Current prostate cancer treatments: effect on quality of life |
| Q39859901 | Effects of selenite and genistein on G2/M cell cycle arrest and apoptosis in human prostate cancer cells |
| Q39569765 | Enhanced TRAIL-mediated apoptosis in prostate cancer cells by the bioactive compounds neobavaisoflavone and psoralidin isolated from Psoralea corylifolia. |
| Q46113402 | Intake of plant foods and associated nutrients in prostate cancer risk |
| Q42084625 | Modulatory effects of Crataeva nurvala bark against testosterone and N-methyl-N-nitrosourea-induced oxidative damage in prostate of male albino rats |
Search more.